Tomoko Yamazaki

机构：Tochigi Cancer Center, Saitama International Medical Center, Saitama Medical University

发表论文 150 篇 · 总被引 5949 次 · h-index 28

代表论文

• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial (2024 · The Lancet Oncology · 被引 231)
• Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial (2022 · Institutional Repositories DataBase (IRDB) · 被引 166)
• Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial (2022 · The Lancet Oncology · 被引 145)
• First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048 (2022 · International Journal of Clinical Oncology · 被引 18)
• A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab (2022 · Scientific Reports · 被引 17)
• First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048 (2024 · International Journal of Clinical Oncology · 被引 10)